Telix Pharmaceuticals is trading 6.5% down at A$15.67 despite the U.S. FDA approving Pixclara on September 14, 2026, as the first FDA-approved FET-PET imaging drug for glioma.
- The approval is a major company-specific development, but available reporting does not explicitly attribute the decline to it.
- The move may reflect profit-taking or other unreported trading factors; no confirmed negative catalyst was identified.